Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence.

p53 is a powerful anti-tumoral molecule frequently inactivated by mutations or deletions in cancer. However, half of all human tumors expresses wild-type p53, and its activation, by antagonizing its negative regulator Mdm2, might offer a new strategy for therapeutic protocol. In this work, we present a molecular dynamics study on Mdm2 structure bound to two different known inhibitors with the aim to investigate the structural transitions between apo-Mdm2 and Mdm2-inhibitor complexes. We tried to gain information about conformational changes binding a benzodiazepine derivative inhibitor with respect the known nutlin and the apo form. The conformational changes alter the size of the cleft and were mainly in the linker regions, suggesting that the overall dynamic nature of Mdm2 is related to dynamic movements in these regions.

[1]  S. Stass,et al.  The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.

[2]  Rafael Brüschweiler,et al.  Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. , 2008, Journal of the American Chemical Society.

[3]  P. Furet,et al.  Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. , 2000, Journal of medicinal chemistry.

[4]  B. Wasylyk,et al.  p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53 , 1999, Oncogene.

[5]  A. Levine,et al.  p53 and E2F-1 cooperate to mediate apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Gabriele Cruciani,et al.  Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition , 2008, J. Chem. Inf. Model..

[7]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[8]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[9]  H. Carlson,et al.  Computational studies and peptidomimetic design for the human p53–MDM2 complex , 2004, Proteins.

[10]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[11]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[12]  David C Fry,et al.  NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.

[13]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[14]  A. Fersht,et al.  Structure of human MDM4 N-terminal domain bound to a single-domain antibody. , 2008, Journal of molecular biology.

[15]  Shubhra Ghosh Dastidar,et al.  Forces mediating protein–protein interactions: a computational study of p53 “approaching” MDM2 , 2010 .

[16]  Chandra S Verma,et al.  Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies , 2010, Cell cycle.

[17]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[18]  A. Fersht,et al.  Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. , 2004, Journal of molecular biology.

[19]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[20]  J. Trujillo-Ferrara,et al.  Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. , 2006, Biopolymers.

[21]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[22]  Berk Hess,et al.  GROMACS 3.0: a package for molecular simulation and trajectory analysis , 2001 .

[23]  Alessandro Pedretti,et al.  VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. , 2002, Journal of molecular graphics & modelling.

[24]  S F Howard,et al.  Molecular characterization of the hdm2-p53 interaction. , 1997, Journal of molecular biology.

[25]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[26]  R. Pellicciari,et al.  Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition , 2009, Proteins.